Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F14%3A00058924" target="_blank" >RIV/00023001:_____/14:00058924 - isvavai.cz</a>
Alternative codes found
RIV/67985823:_____/14:00427797
Result on the web
<a href="http://onlinelibrary.wiley.com/doi/10.1111/1755-5922.12061/abstract" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/1755-5922.12061/abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/1755-5922.12061" target="_blank" >10.1111/1755-5922.12061</a>
Alternative languages
Result language
angličtina
Original language name
Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels
Original language description
AimsStatins have antiinflammatory effects and are known to decrease risk of cardiovascular events and to reduce serum levels of C-reactive protein (CRP), a widely studied biomarker and potential mediator of inflammation and heart disease. However, it isunclear whether statins can block pro-inflammatory effects of human CRP independent of their ability to reduce serum levels of human CRP. Here, we investigated whether rosuvastatin could block pro-inflammatory effects of human CRP without reducing circulating levels of human CRP. Methods and ResultsWe studied the antiinflammatory effects of rosuvastatin in spontaneously hypertensive rats (SHR) transgenically expressing human CRP (CRP-transgenic SHR) and in nontransgenic SHR lacking human CRP (nontransgenic SHR). The CRP-transgenic SHR is characterized by increased serum levels of human CRP and inflammation. In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FB - Endocrinology, diabetology, metabolism, nutrition
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cardiovascular therapeutics
ISSN
1755-5914
e-ISSN
—
Volume of the periodical
32
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
59-65
UT code for WoS article
000332766000006
EID of the result in the Scopus database
—